J Cardiovasc Transl Res. 2026 Jun 8;19(1):66. doi: 10.1007/s12265-026-10788-2.
ABSTRACT
Glutathione, a critical component of cellular antioxidant defences, is metabolized by gamma-glutamyl transferase (GGT), an enzyme increasingly recognized for its role in cardiovascular diseases (CVD). Elevated GGT levels have been associated with a heightened risk of conditions such as heart failure, coronary artery disease, acute coronary events, and adverse cardiovascular outcomes. This study aims to evaluate the role of serum GGT as a cardiac marker for detecting various cardiac diseases and its potential utility in clinical practice. Elevated GGT correlates with several CVD risk factors, including diabetes, hypertension, and metabolic syndrome, and is associated with acute coronary syndromes and myocardial infarction. The study results suggest that serum GGT is a promising biomarker for cardiovascular risk prediction, aiding in the assessment of disease severity and prognosis. GGT has the potential to play a pivotal role in preventive cardiology and personalized medicine, contributing to improved outcomes for patients with CVD.
PMID:42257817 | DOI:10.1007/s12265-026-10788-2